Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat(R) KMT2A + MRD Assay and Software to its industry-leading ...

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat® KMT2A + MRD Assay and Software to its industry-leading ...

Invivoscribe introduces LeukoStrat KMT2A + MRD Assay to advance high-sensitivity leukaemia testing in clinical trials and patient management worldwide: San Diego Friday, February ...

The FDA has expanded the approval of Hologic’s Aptima human papillomavirus (HPV) assay for clinician-collected primary ...

By: Dr. Amrit Kaur Kaler For patients diagnosed with blood cancers such as leukemia, lymphoma, and multiple myeloma, the ...

Precise MRD™ to transition from research-use-only into a limited clinical launch in March 2026SALT LAKE CITY, Jan. 27, 2026 ...

DOVER, DE, UNITED STATES, January 21, 2026 /EINPresswire.com/ -- The global pharmaceutical supply chain is currently ...

Global Drug of Abuse Testing Market Set as Compliance-Driven Screening Becomes a Core Healthcare and Workplace Standard ...

The Minister for Finance, Dr. Cassiel Ato Forson, has announced that Ghana is on course to establish its first modern fire assay laboratory, a move he describes as a historic breakthrough in the ...

Personalis, Inc. , a leader in advanced genomics for precision oncology, today announced the publication of a new study in npj Precision Oncology highlighting the power of its ultrasensitive molecular ...

Natera NTRA recently announced the submission of a premarket approval (PMA) application to the FDA for its Signatera CDx test ...

Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; "Fujirebio"), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and ...